BREAST CÂNCER TREATMENT - NEW DRUGS
Keywords:
Hormoniotherapy, Chemotherapy, New drugs, Breast câncerAbstract
The breast câncer response to hormonal therapy is well known for more than one
century by the results of oophorectomy. Endocrine therapy with tamoxifen, have proved
decreasing in relapses as an adjuvant treatment and also objectives responses in
patient with metastatic disease. Different hormonal strategies have been searched with
the second-generation of anti-oestrogen. These new anti-oestrogen, similars to
tamoxifen, with less side effects, have been studied such as selective oestrogen receptor
modulators.
New chemotherapy drugs studied in the last decade, estabilish one of the highest
progress in the breast câncer chemotherapy. The taxanes are used gathered with
antracyclines in the first line treatment in the worst prognoses cases or kept apart in metastic disease, antimetabolites, tubulin-active drugs and new antracyclines are
appraised in clinicai trials fase III.
Finally, the biological treatment with developing monoclonal antibodies against
the oncoprotein Her2/neu will offer hope for the future. New drugs with less toxicitiy
should be developed considering tumor biological characteristics.
Downloads
References
1.AAPRO MS. Combining new agents with
anthracyclines in metastatic breast câncer: an
overview of recent findings. Semin Oncol 1999;
26: Suppl. 3, 17-21.
2.BARTON BM. Gemcitabine: a pharmacologic and
clinicai overview. Câncer Nurs 1999; 22: 176-83.
3.BASELGA J, NORTON L, ALBANELL J.
Recombinat humanized anti-Her-2 antibody
(Herceptin) enhances the antitumor activity of
paclitaxel and doxorubicin against Her-2/neu
overexpressing human breast câncer xenografts.
Câncer Res 1998; 58: 2825-283.
4.BLAJMAN C. BALBIANI L, BLOCK J et al. A
prospective, randomized phase III trial comparing
combination chemotheraphy with cyclophosphamide,
doxorubicin, and 5-fluorouracil with vinorelbine plus
doxorubicin in the treatment of advanced breast
carcinoma. Câncer 1999; 85: 1091-7.
5.BLUM JL, IONES SE. BUZDAR AU et al.
Multicenter phase II study of capecitabine in
paclitaxel-refractory metastatic breast câncer. J
Clin Oncol 1999: 17:485-93.
6.BUDMAN DR. Vinorelbine (Navelbine): a thirdgeneration vinca alkaloid. Câncer Invest 1997; 15:
475-90.
7.BUZDAR AU. Endocrine theraphy for metastatic
breast câncer. Asco. Educational Book Spring 1999;
522-5.
8.CAPRI G. TARENZI E. FULFARO F. The role of
the taxanes in the treatment of breast câncer. Semin
Oncol 1996; 23: 68-75.
9.COBLEIGH MA, VOGEL CL, TRIPTHAY D.
Efficacy and safety of herceptin (humanized antiHer-2 antibody) as a single agent in 222 women
with Her-2 overexpression who relapsed following
chemotheraphy for metastatic breast câncer. Asco
Proceedings 1998; 17: Abst. 376.
10.ERDKAMP F. CHAN S. DAVIDSON N et al. Phase
III study of TLC D-99 (liposome encaptulated
doxorubicin) plus cyclophosphamide versus
epirubicin (EPI) plus cyclophosphamide (CPA) in
patients with metastatic carcinoma (MBC). Asco
Proceedings 1999; 18: Abst. 459.
11.HORTOBAGYI GN. Treatmen of breast câncer.
N Engl J Med 1998; 339: 974-84.
12.HORTOBAGYI GN. Options for treatment of
metastatic breast câncer. Asco Educational Book
Spring 1999; 515-21.
13.HORTOBAGYI GN. HOLMES FA. Optimal dosing
of paclitaxel and doxorubicin in metastatic breast
câncer. Semin Oncol 1997; 24: S4-7.
14.HURLEY J. RESTREPO A. BOGGS J et al. The
use of neoadjuvant doxil in the treatment of stage
III breast câncer. Asco Proceedings 1999; 18: Abst.
359.
15.KLAASSEN U. LANG S. BORQUEZ D et al. Oral
UFT/leucovorin (LV) in combination with paclitaxel
(P) in the second line treatment of patientes (pts)
with metastatic breast câncer (MBC): results of a
phase I/II trial. Asco Proceedings 1999; Abst. 404.
16.LÜCK HJ. SCHOLZ U, LANGER-NITSCHE C et
al. Câncer adjuvant treatment of breast câncer (BC)
patients with 10 and more limphnodes (LN) with a
sequential therapy of epirubicin/paclitaxel/
cyclophosphamide. A phase II study. Asco
Proceedings 1999; 18: Abst. 366.
17.MAVROUDIS D. MALAMOS N. ALEXOPOULOS
A et al. Salvage chemotheraphy in anthacyclinepretreated metastatic breast câncer patients with
docetaxel and gemcitabine: a multicenter phase II
trial. Greek Breast Câncer Cooperative Group. Ann
Oncol 1999; 10: 211-5.
18.MUSTACCHI G, CECCHERINI R, MUGGIA M
et al. Cisplatinum and vinorelbine (CV) in metastatic
breast câncer (MBC) after anthracycline failure.
Asco Proceedings 1999; 18: Abst. 518.
19.PICCART MJ, AWADA A, HAMILTON A.
Integration of new therapies into management of
metastatic breast câncer: a focus on chemotherapy,
treatment selection through use of molecular
markers, and newly developed biologic therapies
in late clinicai development. Asco Educational Book
Spring 1999; 526-39.
20.SMITH FP, BARR F. HENDRICKSC et al. Phase II
study of Doxil® (pegylated liposomal doxorubicin)
in doxorubicin-resistant, metastatic breast câncer.
Asco Proceedings 1999; 18: Abst. 524.
21.WATANABE T, SANO M. TOKUDA Y et al. Toxicity
profile of UFT (uracil-tegafur) observed in a phase
III randomized comparison of surgical adjuvant
chemotheraphy with UFT versus CMF in high-risk
node negative breast câncer patients a phase II study.
Asco Proceedings 1999; 18: Abst. 397.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Luciano Megale Costa, Auro dei Giglio
This work is licensed under a Creative Commons Attribution 4.0 International License.
